Loading clinical trials...
Loading clinical trials...
The purpose of this study is to compare the overall survival of brivanib versus sorafenib in subjects with advanced HCC who have not received prior systemic therapy.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Bristol-Myers Squibb
NCT07267806 · Hepato Cellular Carcinoma (HCC), Chemotherapy Effect
NCT07148310 · Hepato Cellular Carcinoma (HCC)
NCT06960954 · Hepato Cellular Carcinoma (HCC), Portal Vein Tumour Thrombosis
NCT06812039 · Hepato Cellular Carcinoma (HCC)
NCT06742424 · Hepato Cellular Carcinoma (HCC)
Mayo Clinic Arizona
Scottsdale, Arizona
Univ Of Ark For Med Sci
Little Rock, Arkansas
Agajanian Institute Of Hematology And Oncology
Downey, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions